Meloxicam Decreases the Formation of Peritoneal Adhesions in an Experimental Surgical Model in Rats
Keywords:Cyclooxygenase 2 Inhibitors, Experimental Animal Models, General Surgery, Non-Steroidal Anti-Inflammatory Agents, Tissue Adhesions
Background: Inflammatory adhesions result from an inflammatory response of the peritoneum during an intra-abdominal inflammatory process secondary to thermal or mechanical injury, infection, radiation, ischemia, dissection, abrasion or foreign body reaction. Adhesions produce consequences such as: infertility, intestinal obstruction, and pelvic-abdominal pain. The objective of this study is to evaluate the effects of Meloxicam, a selective cyclooxygenase-2 inhibitor, on the formation of postoperative peritoneal adhesions in an experimental animal model.
Methods: Twenty female Wistar rats were submitted to laparotomy. Postoperative peritoneal adhesions were induced by scorching the serous surface of the colon. The animals were randomly divided into two experimental groups: one group received Meloxicam intramuscularly for 7 days, and the other served as a control group. They were sacrificed and evaluated at 15 days.
Results: In the animals given Meloxicam, it was observed that a decrease in number (p = 0.018), severity (p = 0.004), extension (p = 0.011), density (p = 0.023), degree of inflammation (p = 0.002), vascular proliferation (p = 0.004) and fibrosis (p = 0.029) of adhesions, compared to the control group.
Conclusion: In conclusion, this study demonstrated that the administration of Meloxicam intramuscularly significantly decreases the formation of postoperative peritoneal adhesions and, therefore, may be useful in their prevention. The effects of Meloxicam could not only be due to its anti-inflammatory action, but also to its effects on the expression of the Vascular Endothelial Growth Factor.
2. De Clerq K, Sheltfhout C, Bracke M, De Wever O, Van Bockstal M, Ceelen W, et al. Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: In vitro and in vivo characterization. Bio¬materials. 2016; 96: 33-46.
3. Szomstein S, Lo Menzo E, Simpfendorfer C, Zundel N, Rosenthal RJ. Lapa¬roscopic Lysis of Adhesions. World J Surg. 2006; 30(4): 535-40.
4. Schnuriger B, Barmparas G, Branco BC, Lustenberger T, Inaba K, Demetria¬des D. Prevention of postoperative peritoneal adhesions: a review of the literature. Am J Surg. 2011; 201(1): 111-121.
5. Dubcenco E, Assumpcao L, Dray X, Gabrielson KL, Ruben DS, Pipitone LJ, et al. Adhesion formation after peritoneoscopy with liver biopsy in a survi¬val porcine model: comparison of laparotomy, laparoscopy, and transgastric natural orifice transluminal endoscopic surgery (NOTES). Endoscopy. 2009; 41(11): 971-978.
6. Practice Committee of American Society for Reproductive Medicine in co¬llaboration with Society of Reproductive Surgeons. Pathogenesis, consequen¬ces, and control of peritoneal adhesions in gynecologic surgery: a committee opinion. Fertil Steril. 2013; 99(6): 1550-1555.
7. Rajab TK, Wallwiener M, Talukdar S, Kraemer B. Adhesion-Related Com¬plications Are Common, But Rarely Discussed in Preoperative Consent: A Multicenter Study. World J Surg. 2009; 33(4): 748-750.
8. ten Broek RP, Issa Y, van Santbrink EJ, Bouvy ND, Kruitwagen RF, Jeeker J, et al. Burden of adhesions in abdominal and pelvic surgery: systematic review and met-analysis. BMJ. 2013; 347: f5588.
9. Ward BC, Panitch A. Abdominal Adhesion: Current and Novel Therapies. J Surg Res. 2011; 165(1): 91-111.
10. Ahmad G, Duffy JM, Farquhar C, Vail A, Vandekerchove P, Watson A, et al. Barrier agents for adhesion prevention after gyneacological surgery (Review). Cochrane Database of Syst Rev. 2008;(2):CD000475.
11. Wallwiener M, Brucker S, Hierlemann H, Brochhausen C, Solomayer E, Wallwiener C. Innovative barriers for peritoneal adhesion prevention: liquid or solid? A rat uterine horn model. Fertil Steril. 2006; 86 (4 Suppl): 1266-1276.
12. Ayala M, Ramírez E, Quiroz J, Ortiz J, González B. [Role of alopurinol in peritoneal adherences when placing a polypropylene mesh: Experimental study]. Cir Gen. 2013; 35(1): 16-19.
13. Fotiadis K, Filidou E, Arvanitidis K, Valatas V, Stavrou G, Basdanis G, et al. Intraperitoneal application of phospholipids for the prevention of postope¬rative adhesions: a possible role of myofibroblasts. J Surg Res. 2015;197(2): 291-300.
14. Vázques CJ, Ortiz MM, Sánchez GJR, Reynoso VJ, Gutiérrez I, Gutiérrez C. [Decrease of angiogenesis with spironolactone and captopril and the effect on intraperitoneal adherences]. Cir Gen. 2007; 29(4): 265-268. Spanish.
15. Maciver AH, McCall M, James Shapiro AM. Intra-abdominal adhesions: cellular mechanisms and strategies for prevention. Int J Surg. 2011; 9(8): 589-594.
16. Hoffmann NE, Siddiqui SA, Agarwal S, McKellar SH, Kurtz HJ, Gettman MT, et al. Choice of Hemostatic Agent Influences Adhesion Formation in a Rat Cecal Adhesion Model. J Surg Res. 2009; 155(1): 77-81.
17. Yetkin G, Uludag M, Citgez B, Karakoc S, Polat N, Kabukcuoglu F. Preven¬tion of peritoneal adhesions by intraperitoneal administration of vitamin E and human amniotic membrane. Int J Surg. 2009; 7(6): 561-565.
18. Koninckx P, Corona R, Timmerman D, Verguts J, Adamyan L. Peritoneal full-conditioning reduces postoperative adhesions and pain: a randomised controlled trial in deep endometriosis surgery. J Ovarian Res. 2013; 6(1):90.
19. Huang LN, Yao XM. Inhibitory effect of Meloxicam on the cultured fibro¬blasts from the excised pterygium. Int J Ophthalmol. 2008; 1(1): 48-51.
20. AVECAL (Venezuelan Association for the Science of Laboratory Animals). [Manual for the production and ethical use of laboratory animals]. Ministry of Popular Power for Science and Technology. Caracas. 2008. Spanish.
21. Mayagoitia-Gonzalez JC, Gudiño-Amezcua LM, Rivera-Barragan V, Mella¬do-Diaz AV, Díaz-Chavez EP. [Prevention of intestinal adhesions, through the addition of hyaluronic acid/carboxymethylcellulose gel. Experimental model in rats]. Cir Cir. 2012; 80(2): 150-156.
22. Marentes Etienne JJ, Joya Cervera RE, Rodríguez Hernandez A, Díaz-Cha¬vez EP. [Efficacy of a silicone composite mesh to reduce intra-abdominal adhesions in wistar rats: A preliminary report]. Cir Gen. 2014; 36(4): 205-208. Spanish.
23. Brochhausen C, Schmitt VH, Planck CN, Rajab TK, Hollemann D, Tapprich C, et al. Current strategies and future perspectives for intraperitoneal adhesion prevention. J Gastrointest Surg. 2012; 16(6): 1256-1274.
24. Fredriksson F, Christofferson RH, Carlsson PO, Lilja HE. Locally increased concentrations of inflammatory cytokines in an experimental intrabdominal adhesion model. J Pediatr Surg. 2014; 49(10): 1480-1484.
25. Braun KM, Diamond MP. The Biology of Adhesion Formation in the Perito¬neal Cavity. Semin Pediatr Surg. 2014; 23(6): 336-343.
26. Saed GM, Munkarah AR, Diamond MP. Cycloxygenase-2 is expressed in human fibroblasts isolated from intraperitoneal adhesions but not from nor¬mal peritoneal tissues. Fertil Steril. 2003; 79(6): 1404-1408.
27. Saed GM, Munkarah AR, Abu-Soud HM, Diamond MP. Hypoxia upregulates cycloxygenase-2 and prostaglandin E2 levels in human peritoneal fibroblasts. Fertil Steril. 2005; 83 Suppl 1: 1216-1219.
28. Cahill RA, Wang JH, Soohkai S, Redmond HP. Mast cells facilitate local VEGF release as an early event in the pathogenesis of postoperative peritoneal adhesions. Surgery. 2006; 140(1): 108-112.
29. Cahill RA, Redmond HP. Cytokine orchestration in post-operative peri¬toneal adhesion formation. World J Gastroenterol. 2008; 14(31): 4861-4866.
30. Du XH, Liu JQ, Xin K, Liu GH. Dexamethasone and sodium carboxymethyl cellulose prevent postoperative intraperitoneal adhesions in rats. Braz J Med Biol Res. 2015; 48(4): 344-348.
31. Allahverdi TD, Allaverdi E, Yayla S, Deprem T, Merhan O, Vural S. The Comparison of the Effects of Ellagic Acid and Diclofenac Sodium on Intra-Ab¬dominal Adhesion: An In Vivo Study in the Rat Model. Int Surg. 2014; 99(5): 543-550.
32. Arung W, Jehaes F, Cheramy JP, Defraigne JO, Meurisse M, Honore P, et al. Effects of Parecoxib on The Prevention of Postoperative Peritoneal Adhesions in Rats. J Invest Surg. 2013; 26(6): 340-346.
33. Greene AK, Alwayn IP, Nose V, Flynn E, Sampson D, Zurakowski D, et al. Prevention of Intra-abdominal Adhesions Using the Antiangiogenic COX-2 inhibitor Celecoxib. Ann Surg. 2005; 242(1): 140-146.
34. Guvenal T, Cetin A, Ozdemir H, Yanar O, Kaya T. Prevention of postopera¬tive adhesión formation in rat uterine horn model by nimesulide: a selective COX-2 inhibitor. Hum Reprod. 2001;16(8): 1732-1735.
35. Guvenal T, Yanar O, Timuroglu Y, Cetin M, Cetin A. Effects of selective and non-selective cyclooxygenase (COX) inhibitors on postoperative adhe¬sión formation in a rat uterine horn model. Clin Exp Obstet Gynecol. 2010; 37(1): 49-52.
36. Keskin HL, Akkus SM, Sirens YS, Ustuner I, Keles H, Ide T, et al. Com¬parison of the Effects of Meloxicam and Dexketoprofen on Postoperative Adhesion Formation in a Rat Uterine Horn Surgical Model. J Minim Invasive Gynecol. 2013; 20(2): 185-191.
37. Oliveira TM, Sakai VT, Machado MA, Dionísio TJ, Cestari TM, Taga R, et al. COX-2 Inhibition Decreases VEGF Expression and Alveolar Bone loss During the Progression of Experimental Periodontitis in Rats. J Periodontol. 2008; 79(6): 1062-1069.
38. Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H. Inhibitory Effects of Meloxicam, a Selective Cyclooxygenase-2 inhibitor, and Ciglitazone, a Pe-roxisome Proliferator-Activated Receptor Gamma Ligand, on the Growth of
Human Ovarian Cancers. Cancer. 2007; 110(4): 791-800.
39. Quintana R, Kopcow L, Marconi G, Young E, Yovanovich C, Paz DA. Inhibi¬tion of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril. 2008; 90 (4 Suppl): 1511-1516.
How to Cite
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to firstname.lastname@example.org
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to email@example.com